Victory Capital Management Reduces Stake in Supernus Pharmaceuticals

Institutional investor sells nearly 200,000 shares of specialty pharmaceutical company

Published on Mar. 10, 2026

Got story updates? Submit your updates here. ›

Victory Capital Management Inc., an institutional investor, decreased its position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 25.5% during the third quarter, according to a recent SEC filing. The firm sold 191,708 shares, leaving it with 559,835 shares of the specialty pharmaceutical company's stock, valued at $26.8 million.

Why it matters

Supernus Pharmaceuticals is a key player in the specialty pharmaceutical industry, focused on developing and commercializing central nervous system therapies. The reduction in ownership by a major institutional investor like Victory Capital Management could signal a shift in market sentiment or outlook for the company.

The details

According to the SEC filing, Victory Capital Management sold 191,708 shares of Supernus Pharmaceuticals during the third quarter, reducing its total stake in the company to 559,835 shares. This represents a 25.5% decrease in the firm's position. Supernus Pharmaceuticals is a specialty pharmaceutical company that focuses on treatments for neurological disorders, including antiepileptic medications and an ADHD drug.

  • Victory Capital Management filed the SEC disclosure on March 10, 2026, reporting its third quarter 2025 trading activity.
  • The firm sold the Supernus Pharmaceuticals shares during the third quarter of 2025.

The players

Victory Capital Management Inc.

An institutional investment management firm that decreased its position in Supernus Pharmaceuticals by 25.5% in the third quarter of 2025.

Supernus Pharmaceuticals, Inc.

A specialty pharmaceutical company focused on developing and commercializing central nervous system therapies, including antiepileptic medications and an ADHD drug.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee (Instagram)

The takeaway

The reduction in ownership by a major institutional investor like Victory Capital Management could signal a shift in market sentiment or outlook for Supernus Pharmaceuticals, a key player in the specialty pharmaceutical industry. Investors will likely be watching to see if other large investors follow suit or if Supernus can maintain its momentum in the CNS therapy market.